Systemic drug therapy and restenosis after drug-eluting stent implantation.
- Author:
Kyoo Rok HAN
1
Author Information
1. Department of Internal Medicine, College of Medicine, Hallym University, Seoul, Korea.
- Publication Type:Editorial ; Clinical Trial
- Keywords:
Drug-eluting stent;
Restenosis;
Systemic drug therapy;
Cilostazol
- MeSH:
Drug-Eluting Stents;
Hyperplasia;
Percutaneous Coronary Intervention;
Stents;
Tetrazoles
- From:Korean Journal of Medicine
2008;74(4):366-367
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Until now restenosis is one of the most important issues after stent implantation. Use of systemic drug therapy to inhibit post-stent restenosis has been largely unsuccessful. Drug-eluting stents (DES) have been shown to significantly reduce restenosis after percutaneous coronary intervention. However we still experience lots of problems associated with restenosis even after DES implantation. Recently some clinical trials have suggested that cilostazol reduces intimal hyperplasia and lowers restenosis after bare metal stents (BMS) implantation. It is uncertain that cilostazol can also reduce restenosis after DES implantation. We need more large clinical trials to elucidate the efficacy of cilostazol on restenosis after DES implantation.
